Drug Profile
Research programme: antibody-drug conjugates - Advanced Proteome Therapeutics/ImmunoBiochem
Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Advanced Proteome Therapeutics; ImmunoBiochem
- Class Antineoplastics; Immunoconjugates
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Triple negative breast cancer
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for research development in Triple negative Breast-cancer in USA (Parenteral)
- 07 Feb 2018 Advanced Proteome Therapeutics and ImmunoBiochem Corporation enter into a collaboration and option agreement for development of antibody-drug conjugates for Breast cancer
- 07 Feb 2018 Early research in Triple negative Breast cancer in USA (Parenteral)